IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
HIV Prevention Preparedness Study
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition |
|---|
| HIV Infections HIV Seronegativity |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | HIV Prevention Preparedness Study |
| Estimated Enrollment: | 1200 |
This study is designed to prepare for the implementation of a second study, HPTN 035: A Phase II/III Safety and Effectiveness Study of the Vaginal Microbicides BufferGel and PRO 2000/5 Gel (P) for the Prevention of HIV Infection in Women. HPTN 035 requires an average HIV seroincidence rate of 5-6 percent among enrolled participants. The primary objective of the present study is to estimate the rates of HIV seroincidence among women targeted for inclusion in HPTN 035.
Women will be enrolled in this study for 6 to 12 months. Study visits will take place monthly. At each visit, participants will complete a medical/menstrual history and undergo pregnancy testing. Each quarter, participants will undergo a structured interview about sexual practices and will receive HIV and STD tests, education, and counseling. Participants will also undergo a pelvic exam with wet mount testing for bacterial vaginosis, candidiasis, and trichomoniasis. Colposcopic evaluations will be performed at selected sites. Pap smears will be performed at sites with the capacity and expertise to prepare and interpret the smears and provide appropriate follow-up care to participants with abnormal results.
Eligibility| Ages Eligible for Study: | Child, Adult, Senior |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
- Sexually active (defined as having had vaginal intercourse at least once in the 3 months prior to screening).
- HIV-uninfected at screening.
- Able and willing to provide adequate locator information for study retention purposes.
Exclusion criteria:
- History of adverse reaction to latex.
- Non-therapeutic injection drug use in the 12 months prior to screening.
- Vaginal intercourse more than an average of 2 times per day in the 2 weeks prior to screening.
- Plans to travel away from the study site for more than 3 consecutive months in the next 12 months.
- Plans to relocate away from the study site in the next 12 months.
- Pregnancy or plans to become pregnant in the next 12 months.
- Pregnancy within 42 days prior to enrollment.
- Enrollment in any other study of a vaginally-applied product.
- Clinically apparent pelvic exam finding involving deep epithelial disruption.
- Diagnosis with a current STD and/or other reproductive tract infection requiring treatment.
- Conditions that would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT00048282
| South Africa | |
| R.K. Khan Hospital | |
| Chatsworth, South Africa | |
| Durban, South Africa | |
| Medical Research Council | |
| Hlabisa, South Africa | |
| Hlabisa, South Africa | |
| Tanzania | |
| Kilimanjaro Christian Med Ctr | |
| Moshi, Tanzania | |
| Moshi, Tanzania | |
| Zambia | |
| Chililabombwe, Zambia | |
| Chilenje Clinic, Lusaka, Sambia | |
| Lusaka, Zambia | |
| Kamwala Clinic | |
| Lusaka, Zambia | |
| Lusaka, Zambia | |
| Study Chair: | Saidi Kapiga, MD, MPH, SCD | Harvard School of Public Health |
| Study Chair: | Gita Ramjee, PhD | South Africa Medical Research Council |
| Study Chair: | Stephen Weiss, PhD | University of Miami |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00048282 History of Changes |
| Other Study ID Numbers: |
HIVNET/HPTN 055 |
| Study First Received: | October 29, 2002 |
| Last Updated: | May 13, 2010 |
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
|
Incidence HIV Seroprevalence Vagina Anti-Infective Agents |
Administration, Topical Gels HIV Seronegativity |
Additional relevant MeSH terms:
|
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases |
ClinicalTrials.gov processed this record on June 23, 2017